cis-Dichlorodiammineplatinum(II) alone and combined with DTIC for treatment of disseminated malignant melanoma

James E Goodnight Jr, H. S. Moseley, F. R. Eilber, G. Sarna, D. L. Morton

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

Twenty-one patients with disseminated malignant melanoma were treated with cis-dichlorodiammineplatinum(II) (cis-DDP): ten with cis-DDP alone at a dose of 20 mg/m 2iv x 4 days every 4 weeks and 11 with cis-DDP at a dose of 15 mg/m 2 iv x 4 days combined with DTIC at a dose of 200 mg/m 2 iv x 5 days every 4 weeks. Two of 21 patients (10%) showed a partial response to therapy. There were no complete responses and no apparent increases in length of survival for responders compared to nonresponders. One drug-related death occurred. Otherwise, drug toxicity was acceptable and appeared to be diminished by iv hydration and prolonged administration. In this study, cis-DDP was not effective for treatment of disseminated malignant melanoma.

Original languageEnglish (US)
Pages (from-to)2005-2007
Number of pages3
JournalCancer Treatment Reports
Volume63
Issue number11-12
StatePublished - 1979

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'cis-Dichlorodiammineplatinum(II) alone and combined with DTIC for treatment of disseminated malignant melanoma'. Together they form a unique fingerprint.

  • Cite this